CMPX vs CRDF

Compass Therapeutics, Inc. vs Cardiff Oncology, Inc. — Valuation Comparison 2026

CMPX

Biological Products, (No Diagnostic Substances)
Compass Therapeutics, Inc.
Quality
5.3
out of 10
Value Trap
30
LOW
Price
$2.38
Last close
Models
9/13
Active
VS

CRDF

Biological Products, (No Diagnostic Substances)
Cardiff Oncology, Inc.
Quality
5.9
out of 10
Value Trap
30
LOW
Price
$1.90
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CMPX Fair ValueCMPX Upside CRDF Fair ValueCRDF Upside
Bayesian DCF Intrinsic $0.66 -72.5% $0.57 -70.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.18 -90.4% $0.06 -96.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CMPX vs CRDF — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CMPX vs CRDF — Which Stock Is More Undervalued?

CRDF scores higher with a 5.9/10 quality rating vs CMPX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Compass Therapeutics, Inc. (CMPX) and Cardiff Oncology, Inc. (CRDF) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CMPX currently trades at $2.38 with a QOC of 5.3/10, while CRDF trades at $1.90 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).